WO2023277222A1 - 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 - Google Patents
돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 Download PDFInfo
- Publication number
- WO2023277222A1 WO2023277222A1 PCT/KR2021/008308 KR2021008308W WO2023277222A1 WO 2023277222 A1 WO2023277222 A1 WO 2023277222A1 KR 2021008308 W KR2021008308 W KR 2021008308W WO 2023277222 A1 WO2023277222 A1 WO 2023277222A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- hydrolyzate
- enzyme
- placenta
- pig
- Prior art date
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 239000002253 acid Substances 0.000 title claims abstract description 91
- 239000000413 hydrolysate Substances 0.000 title claims abstract description 44
- 210000004185 liver Anatomy 0.000 title claims abstract description 23
- 230000002255 enzymatic effect Effects 0.000 title abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 206010067125 Liver injury Diseases 0.000 claims abstract description 17
- 231100000234 hepatic damage Toxicity 0.000 claims abstract description 15
- 230000008818 liver damage Effects 0.000 claims abstract description 15
- 206010019133 Hangover Diseases 0.000 claims abstract description 11
- 206010013663 drug dependence Diseases 0.000 claims abstract description 11
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims description 112
- 108090000790 Enzymes Proteins 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 230000036541 health Effects 0.000 claims description 30
- 235000013376 functional food Nutrition 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 102000035195 Peptidases Human genes 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 235000013305 food Nutrition 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 3
- 241000282898 Sus scrofa Species 0.000 description 107
- 229940088598 enzyme Drugs 0.000 description 107
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 230000003169 placental effect Effects 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 108010082126 Alanine transaminase Proteins 0.000 description 22
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 22
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 22
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000004885 tandem mass spectrometry Methods 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 8
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 7
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 7
- 229960004245 silymarin Drugs 0.000 description 7
- 235000017700 silymarin Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010088535 Pep-1 peptide Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 pH regulators Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010046002 Pep-3 peptide Proteins 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008380 degradant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940032362 superoxide dismutase Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YFONIXLMYIFMNK-UHFFFAOYSA-N 2-methyl-1,3-thiazole;1h-tetrazol-1-ium;bromide Chemical compound [Br-].[NH2+]1C=NN=N1.CC1=NC=CS1 YFONIXLMYIFMNK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000009017 Fluorometric Assay Kit Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108010091431 meat tenderizer Proteins 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to a composition for protecting the liver comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate.
- the liver is one of the organs in the human body in which metabolism is most active. It can be caused by various causes, such as excessive consumption of food or alcohol containing fat, viral infection, harmful substances such as various medicines, and lack of nutrition. Chronic disorders occur, and fatty liver, hepatitis, jaundice, cirrhosis of the liver, and liver cancer may be caused. In particular, excessive fat intake through food or excessive alcohol intake causes fatty liver in which lipids are accumulated in liver tissue, and at this time, AST (aspartate transaminase), ALT (alanine transaminase), and LDH (lactate dehydrogenase) in serum increase.
- AST aspartate transaminase
- ALT alanine transaminase
- LDH lactate dehydrogenase
- the placenta is composed of blood chorion and supplies necessary oxygen and nutrients to the fetus while maintaining contact between the fetus and maternal tissue. It also plays an important role in eliminating waste products produced by the fetus.
- the placenta contains various nutrients and hormones necessary for the growth of the fetus, and pig placenta is widely used in adults, especially for menopausal symptom relief and cosmetic purposes.
- the placenta contains essential amino acids, melatonin, nucleic acid components such as RNA and DNA, antioxidant enzymes such as SOD (Super Oxide Dismutase), hyaluronic acid, antioxidants, cytokines, placenta peptides, insulin-like growth promoters, and epidermal growth promoters. It is known to be useful for fatigue recovery and immunity enhancement because it contains growth factors and cytokines such as (EGF) and senescent cell activator (SCAF).
- EGF epidermal growth promoters
- porcine placenta has high homology with the protein structure of human placenta among mammalian placentas, and porcine placenta is an important component of protein, various nutrients, DNA and RNA, and is a bio-active cytokine that governs cell differentiation and fetal development. has been reported as a source of Due to these characteristics, pig placenta is applied to food and medicine. However, research on a porcine placenta composition that can effectively prevent or improve alcohol-induced liver damage, drug addiction, hangover, etc. is still lacking.
- An object of the present invention is to provide a health functional food composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- Another object of the present invention is to provide a health functional food composition for preventing or improving alcohol-induced liver damage, drug addiction or hangover, comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating alcohol-induced liver damage, drug addiction or hangover, comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the present invention provides a health functional food composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the present invention provides a health functional food composition for preventing or improving alcohol-induced liver damage, drug addiction, or hangover, comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the pig placental enzyme hydrolyzate may include one or more peptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3.
- the pig placenta enzyme hydrolyzate and acid hydrolyzate may be mixed in a weight ratio of 1:0.1 to 10, preferably 1:0.5 to 5, 1:0.6 to 5, 1: 0.7 ⁇ 5, 1:0.8 ⁇ 5, 1:0.9 ⁇ 5, 1:1 ⁇ 5, 1:1 ⁇ 4, 1:1 ⁇ 3, 1:1, 1:2, 1:3, 1:4 or It may be mixed in a weight ratio of 1:5, but is not limited thereto.
- the pig placental enzyme hydrolyzate may be prepared by treating a proteolytic enzyme, and the proteolytic enzyme is composed of papain, pronase, bromelain and alcalase. It may be selected from the group, but is not limited thereto.
- the pork placenta acid decomposition product may be prepared by treating an acid, and the acid may be hydrochloric acid, sulfuric acid, acetic acid or citric acid, but is not limited thereto no.
- the peptide may be included in a concentration of 0.1 ppm to 100 ppm, preferably in a concentration of 1 to 25 ppm in the pig placenta enzyme hydrolyzate.
- the mixture of the pig placenta enzyme hydrolyzate and the acid hydrolyzate may be included in an amount of 1% to 20% by weight based on the total weight of the health functional food composition.
- the peptide may be included in a concentration of 0.001 ppm to 20 ppm in the entire composition.
- the composition may reduce the levels of alkaline phosphatase (ALP), aspartate transaminase (AST) or alanine transaminase (ALT) in serum.
- ALP alkaline phosphatase
- AST aspartate transaminase
- ALT alanine transaminase
- the present invention provides a pharmaceutical composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating alcohol-induced liver damage, drug addiction, or hangover, comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the mixture of the pig placenta enzyme hydrolyzate and the acid hydrolyzate may be included in an amount of 5% to 30% by weight based on the total weight of the pharmaceutical composition.
- the peptide may be included in a concentration of 0.005 ppm to 30 ppm in the entire composition.
- composition according to the present invention has a remarkable effect on liver protection and, in particular, has a remarkable effect on preventing, improving or treating alcohol-induced liver damage, so it can be usefully used in the fields of medicine and pharmacy and food.
- VVVE porcine placenta enzyme hydrolysates and peptides
- VVVE pig placental enzyme hydrolysates and peptides
- DGLHLR porcine placental enzyme hydrolysates and peptides
- DDFNPSVH porcine placenta enzyme hydrolysates and peptides
- ADH alcohol dehydrogenase
- A-form pig placenta Acid degradant administration group
- the present invention proposes a health functional food composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the present invention in its best form, proposes a health functional food composition for preventing or improving liver damage caused by alcohol, drug addiction or hangover, comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient.
- the present invention is a health functional food composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient; And it provides a health functional food composition for preventing or improving liver damage caused by alcohol, drug addiction or hangover.
- the pig placental enzyme hydrolyzate may include one or more peptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3.
- the peptide may be included in a concentration of 0.1 ppm to 100 ppm, preferably in a concentration of 1 to 25 ppm in the pig placental enzyme hydrolyzate.
- proteolytic enzyme hydrolysate refers to a product prepared by treating porcine placenta with a proteolytic enzyme.
- the proteolytic enzyme may be selected from the group consisting of papain, pronase, bromelain, and alcalase, but is not limited thereto.
- porcine placenta acid hydrolyzate refers to a product prepared by acid-treating porcine placenta.
- the acid may be hydrochloric acid, sulfuric acid, acetic acid or citric acid, but is not limited thereto.
- the pig placenta enzyme hydrolyzate and acid hydrolyzate may be mixed in a weight ratio of 1:0.1 to 10, preferably 1:0.5 to 5, 1:0.6 to 5, 1:0.7 to 5, 1:0.8 to 5 , 1:0.9-5, 1:1-5, 1:1-4, 1:1-3, 1:1, 1:2, 1:3, 1:4 or 1:5 mixed in a weight ratio It may, but is not limited thereto.
- the health functional food composition of the present invention may include all foods in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food and health functional food.
- health functional food refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionalities for the human body.
- 'functionality' means obtaining useful effects for health purposes, such as adjusting nutrients for the structure and function of the human body or physiological functions.
- the health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation.
- the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food.
- the health functional food composition of the present invention uses food as a raw material and has the advantage of not having side effects that can occur when taking medicine for a long time, and has excellent portability, preventing liver damage caused by alcohol, drug addiction or hangover Or it can be taken as an adjuvant to enhance the improvement effect.
- the active ingredient may be included in an amount of 1% to 20% (% by weight) based on the total weight of the composition, but is necessarily limited thereto. It is not, and the mixing amount of active ingredients can be appropriately determined according to each purpose of use such as prevention, health or treatment.
- the formulation of the health functional food may be in the form of a powder, granule, pill, tablet, or capsule, as well as a general food or beverage form.
- the type of food is not particularly limited, and examples of food to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and dairy products including ice cream. , various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and may include all foods in a conventional sense.
- the active ingredient when preparing food or beverage, may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on 100 parts by weight of the raw material.
- the amount in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since the present invention uses fractions from natural products, there is no problem in terms of safety, so the above range The above amount can also be used.
- beverages may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages.
- the aforementioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- sweetener natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
- the ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.
- the health functional food composition according to the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, It may contain glycerin, alcohol, and carbonation agents used in carbonated beverages.
- the health functional food composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not limited, but the functional food composition of the present invention is generally selected from the range of 0.01 to 0.1 parts by weight based on 100 parts by weight.
- the present invention provides a pharmaceutical composition for liver protection comprising a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate as an active ingredient; And it provides a pharmaceutical composition for preventing or improving liver damage caused by alcohol, drug addiction or hangover.
- the pharmaceutical composition according to the present invention is not particularly limited in content as long as it contains the active ingredient, but preferably the active ingredient may be included in 5 to 30% by weight based on the total weight of the composition. However, it is not limited thereto.
- the peptide may be included in a concentration of 0.005 ppm to 30 ppm in the entire composition. At this time, when the peptide is less than the above concentration range, there is a problem that it is difficult to exert a desirable preventive or therapeutic effect, and when the peptide exceeds the above concentration range, the change in the expected effect may be insignificant.
- the pharmaceutical composition according to the present invention is formulated according to conventional methods into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions.
- oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions.
- suitable carriers, excipients or diluents commonly used in the preparation of pharmaceutical compositions may be included.
- carrier or excipient or diluent examples include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undecided various compounds or mixtures including vaginal cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- diluents or excipients such as commonly used fillers, weighting agents, binders, wetting agents, disintegrants, and surfactants.
- a solid preparation for oral administration may be prepared by mixing the jasmon with at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like.
- excipients for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like.
- lubricants such as magnesium stearate and talc may also be used.
- Liquid preparations for oral administration include suspensions, solutions for oral use, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc. may be included in addition to water and liquid paraffin, which are commonly used simple diluents. .
- Formulations for parenteral administration include sterilized aqueous solutions, water-insoluble agents, suspensions, emulsions, freeze-dried preparations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions.
- injectable esters such as ethyl oleate
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerol gelatin, and the like can be used.
- a preferred dosage of the pharmaceutical composition according to the present invention varies depending on the patient's condition, body weight, disease severity, drug type, administration route and period, but can be appropriately selected by those skilled in the art. However, for desirable effects, it may be administered at 0.0001 to 2,000 mg/kg per day, preferably 0.001 to 2,000 mg/kg. Administration may be administered once a day or divided into several times. However, the scope of the present invention is not limited by the dosage.
- the pharmaceutical composition according to the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes. All modes of administration can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
- the pig placenta After the pig placenta is thawed in a thawing machine, the pig placenta, which has been removed with water, is put in a meat tenderizer to be tenderized to facilitate blood removal. Thereafter, the placenta was washed several times with 0.9% NaCl to remove blood from the placenta, and the placenta was crushed to facilitate hydrolysis using a blender. 3% of a proteolytic enzyme (papain) was added to the porcine placenta prepared as described above, and hydrolysis was performed for 20 hours.
- papain proteolytic enzyme
- the proteolytic enzyme was inactivated by heating, and the porcine placenta hydrolyzate was brought into contact with a filter aid, followed by filtration and adsorption purification. Thereafter, 1.2-fold (w/w) ethanol was added to the filtrate of the hydrolyzate of the pig placenta, and after being allowed to stand for 15 to 20 hours, a filter was used to remove sugars, proteins, and impurities that were not sufficiently hydrolyzed. After concentrating the filtrate, adsorption and purification using 0.1 to 2% of activated carbon, the used activated carbon was removed by filtration using a filter. The purified porcine placental enzyme hydrolyzate from which activated carbon was removed was sterilized by sterilization and filtration through a 0.2 ⁇ m filter. Finally, a high-purity placenta extract was obtained.
- the present inventors performed an experiment to analyze the nitrogen content, amino acid content and HPLC pattern of the prepared pig placenta enzyme hydrolysate and acid hydrolyzate in order to confirm the characteristics of the pig placenta enzyme hydrolyzate and the acid hydrolyzate.
- the amino acid content was about 40%, and in the case of the acid hydrolyzate, the amino acid content was about 80% (Table 1). That is, it was confirmed that the amino acid content was higher in the acid hydrolyzate than in the enzyme hydrolyzate.
- the HPLC patterns of the pig placenta enzyme hydrolyzate and the acid hydrolyzate were also different (FIG. 1).
- H 2 O/FA 100/0.2 (v/v)
- a peptide having the same mass and ms/ms ionization form as the peptide identified from the porcine placenta enzyme hydrolysate was synthesized from Anygen (www.anygen.com), and subsequent experiments were conducted.
- the peptide was verified in two ways.
- chromatograms of pig placental enzyme hydrolysates and peptides were analyzed.
- Pig placenta hydrolysate (A), peptide (VVVE) (B) and pig placenta hydrolysate were spiked with synthetic peptides (C) to confirm the chromatogram.
- the pig placenta hydrolyzate and the synthetic peptide were determined to have the same peak.
- the peptides were consistent with components present in the porcine placenta hydrolysate (FIG. 3).
- porcine placental enzyme hydrolysates and peptides were analyzed.
- Pig placenta hydrolysate (A), peptide (DGLHLR) (B) and pig placenta hydrolysate were spiked with synthetic peptides (C) to confirm the chromatogram.
- the pig placenta hydrolyzate and the synthetic peptide were identified as the same peak.
- the peptides were identical to the components present in the porcine placenta hydrolysate (FIG. 5).
- HepG2 cells a hepatic cancer cell line
- a hepatic cancer cell line were dispensed in a 24-well plate at 1 ⁇ 10 5 /well and cultured. Thereafter, in order to confirm the hepatocellular protective ability of the three synthetic peptides, the peptides were treated at each concentration and cultured for 23 hours, and then treated with 10 mM t-BHP to damage liver cells and cultured for 90 minutes.
- PEP-2 and PEP-3 showed high hepatocellular protective ability of 26% and 20%, respectively, at 10 ⁇ ug/ml (Table 5).
- each well (1 x 10 5 /well) was treated with three synthetic peptides at each concentration and cultured for 23 hours, then treated with 20 mM t-BHP and cultured for 3 hours. Then, the supernatant was taken and measured using Aspartate transaminase (AST or SGOT) Activity Colorimetric Assay Kit (BIOVISION; K753-100).
- PEP-2 and PEP-3 each showed the most significant AST inhibitory ability at 10 ⁇ g/ml, and the values were 34% and 14% (Table 6). As shown in the results of hepatocellular protective ability, it was confirmed that PEP-2 showed the most excellent efficacy.
- each well (1 x 10 5 /well) was treated with three synthetic peptides at each concentration and cultured for 23 hours, then treated with 20 mM t-BHP and cultured for 3 hours. Then, the supernatant was taken and measured using Alanine transaminase (ALT or SGPT) Activity Colorimetric/Fluorometric Assay Kit (BIOVISION; K752-100).
- ALT or SGPT Alanine transaminase
- BIOVISION BIOVISION; K752-100
- the supernatant was removed and reacted for 4 hours using an MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), followed by 400 ⁇ l of DMSO. The insoluble formazan crystals were dissolved by putting in each, and the absorbance was measured with an ELISA reader (TECAN, Infinite M200 pro) at a wavelength of 570 nm.
- the present inventors performed a cytotoxicity test of the pig placenta enzyme hydrolysate and acid lysate by measuring the cell viability after treating the human liver cancer cell line with the pig placenta enzyme hydrolysate and acid lysate. Briefly, HepG2 human liver cancer cell line was cultured in a cell culture flask and dispensed at a cell number of 1.5x10 5 in a 24 well plate when it reached 80% confluence. After culturing for 48 hours, each test substance was treated for each concentration and further cultured for 24 hours.
- HepG2 human liver cancer cell line was cultured in a cell culture flask and then dispensed into a 24 well plate at a cell number of 1.5x10 5 when reaching 80% confluence. After culturing for 48 hours, each test substance was treated by concentration and cultured for 23 hours. Then, t-BHP (tert-Butyl hydroperoxide, 10 mM) was simultaneously treated with the sample for 1 hour and 30 minutes on the cells. After 1 hour and 30 minutes of concurrent treatment, MTT was compared to the liver injury treatment group damaged by t-BHP to confirm the protective ability of hepatocytes.
- t-BHP tert-Butyl hydroperoxide, 10 mM
- the present inventors conducted an experiment to confirm the effect of the pig placental enzyme hydrolysate and the acid hydrolyzate on inhibiting hepatotoxicity. After culturing the HepG2 human liver cancer cell line in a cell culture flask, when it reached 80% confluence, it was dispensed into a 24 well plate at a cell number of 1.5x10 5 . After culturing for 48 hours, each test substance was treated by concentration and cultured for 23 hours.
- liver function improvement efficacy of porcine placenta enzyme hydrolysates and acid hydrolysates division cytotoxicity
- Hepatocellular protective ability AST inhibition ALT inhibition enzyme hydrolysate non-toxic (0.5 mg/ml) About 40% protection (0.05mg/ml) 91% (0.1mg/ml) 23% (0.1mg/ml) acid hydrolyzate non-toxic (0.5 mg/ml) About 21% protection (0.05mg/ml) 93% (0.1mg/ml) no change (0.1mg/ml)
- the present inventors in order to confirm the characteristics of a mixture of a pig placenta enzyme hydrolyzate and an acid hydrolyzate by ratio, used a weight ratio of 1:1, 1:2, 1:3, and 1:4 After mixing, an experiment was performed to analyze the nitrogen content and amino acid content.
- Example 7 Alcoholic liver damage of porcine placenta enzymatic hydrolysates, acid lysates and mixtures of porcine placenta enzymatic hydrolysates and acid lysates. in vivo Efficacy evaluation
- Powder samples were prepared by spray drying porcine placenta enzyme hydrolysates, acid hydrolysates, and mixtures of enzyme hydrolysates and acid hydrolysates. Therefore, in order to confirm the characteristics of the powder sample, the nitrogen content and amino acid content of the powder sample were analyzed (Table 8).
- Porcine placenta enzymatic hydrolysates, acid lysates, and mixtures of enzymatic hydrolysates and acid lysates are divided Total Nitrogen (mg/mL) Amino Acids (mg/mL) amino acid % Peptide % enzyme hydrolysate 46.79 125.25 42.5 57.5 acid hydrolyzate 35.70 197.38 81.2 18.8 A mixture of enzyme and acid digest (1:3) 39.27 176.27 64.0 36.0
- the recipe for the alcoholic diet is as follows: 1) Place the required weight of powdered feed (132.28 g) in a beaker with 67 ml of alcohol (spirit) plus 821 ml of water; 2) After adding enough water, stir enough to avoid clumps; 3) Add water up to the marked 1L portion; 4) After thoroughly stirring the feed, put it in a blender and mix for 30 seconds; and 5) using a Feeding Tube (120 ml).
- liquid diet is used in a regular feeding trough, it may overflow or easily stick to the animal's body, resulting in a large loss.
- highly volatile alcohol is easily blown away or its diet is easily oxidized, which can have a great effect on the experiment. Therefore, in this experiment, a food container for liquid food was used.
- test group is as follows.
- Negative control group Alcohol diet (free feeding for 4 weeks) + 30% alcohol (1.4 g/kg, PO) 2 additional administrations at 4 weeks
- Porcine placenta enzyme hydrolyzate high-dose group 2511 mg/kg/day, PO+alcohol diet (free feeding for 4 weeks) + 30% alcohol (1.4 g/kg, PO) 2 additional administrations at 4 weeks
- Pig placenta acid hydrolyzate high-dose group 3282 mg/kg/day, PO+alcohol diet (free feeding for 4 weeks) + 30% alcohol (1.4 g/kg, PO) 2 additional administrations at 4 weeks
- the present inventors performed the experiment for 4 weeks according to the protocol after pre-breeding the test animals for about 1 week.
- the test sample was prepared at a dose of a predetermined concentration every day and administered orally once. At the 4th week, two additional doses were orally administered at the prescribed dose.
- the blood was collected by cardiac blood collection, and the blood was centrifuged at 3000 rpm, and the serum was quantified with an alcohol kit and an acetaldehyde kit, and the blood concentration was compared and analyzed.
- blood collection for liver toxicity evaluation was put into a heparin tube as cardiac blood collection, and after centrifugation at 10,000 rpm for 10 minutes, liver enzyme levels were measured to evaluate liver toxicity. A portion of the tissue was taken to evaluate liver tissue changes and intrahepatic ADH and ALDH enzymatic activities. All results were mean and standard error, and the significance between test groups was verified by Student's t-test and ANOVA test.
- serum indicators ALP, ALT, and AST, which represent liver disease, as well as albumin and total protein, which represent liver synthesis capacity, are measured to determine the efficacy of pig placenta for liver inflammation as well as comprehensive liver status of liver synthesis capacity attempted to verify.
- the measured values for each serum index are shown in Table 5.
- serum albumin is an indicator of hepatosynthetic ability along with total protein, and no significant difference was found in the indicators for each group.
- ALP alkaline phosphatase
- silymarin, pig placenta extract a test substance
- pig placental enzyme hydrolysates were confirmed to be significantly reduced.
- ALT and AST are representative aminotransferases that show liver function.
- the ALT level increased by about 3.5 times compared to the normal control group, and when the test substance (silymarin, porcine placenta extract) was administered, it was confirmed that it decreased compared to the negative control group.
- the test substance saliva, porcine placenta extract
- the ALT level was decreased in a dose-dependent manner, and the ALT level decreased most remarkably at the high dose of the mixture of pig placenta enzyme hydrolyzate and acid hydrolyzate.
- the AST level was significantly increased due to hepatotoxicity compared to the normal control group, and the AST level was significantly decreased in all test groups except for the high dose of the enzyme hydrolyzate in the test substance.
- the AST level decreased in a dose-dependent manner, as in ALT, when the mixture of the hydrolyzate and the acid hydrolyzate of the pig placenta was administered.
- a mixture of porcine placenta enzyme hydrolysate and acid hydrolyzate (mixed at a weight ratio of 1:3) was dissolved in distilled water at a concentration of 100 mg/100 ml (0.1% by weight) or 15,000 mg/100 mL (15% by weight), respectively.
- distilled water was dissolved in distilled water at a concentration of 100 mg/100 ml (0.1% by weight) or 15,000 mg/100 mL (15% by weight), respectively.
- oligosaccharide 2% by weight
- sugar 2% by weight
- salt (0.5% by weight
- An injection was prepared by dissolving 1 mg of a mixture of pig placenta enzyme hydrolyzate and acid hydrolyzate (mixed at a weight ratio of 1:3) in 5 ml of distilled water or physiological saline and sterilized. Alternatively, it was prepared as a powder formulation after lyophilization in a vial.
- Capsules were prepared by filling 100 mg of porcine placenta hydrolyzate, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate into gelatin capsules.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
구분 | 총 질소(mg/mL) | 아미노산(mg/mL) | 아미노산 % | 펩타이드 % |
효소가수분해물 | 5.30 | 13.68 | 41.1 | 58.9 |
산 분해물 | 5.67 | 31.72 | 81.2 | 18.8 |
Step (%) | Total Time(min) | Flow Rate(μl/min) | A(%) | B(%) |
0 | 0.00 | 200 | 95 | 5 |
1 | 5.00 | 200 | 95 | 5 |
2 | 28.00 | 200 | 70 | 30 |
3 | 33.00 | 200 | 5 | 95 |
4 | 40.00 | 200 | 5 | 95 |
5 | 41.00 | 200 | 95 | 5 |
6 | 46.00 | 200 | 95 | 5 |
No. | m/z | RT(min) | Charge | Sequence | Organism |
1 | 445.27 | 10.0 | 1 | VVVE | Sus scrofa (Pig) |
2 | 571.27 | 11.5 | 1 | QMHR | - |
3 | 355.70 | 14.5 | 2 | DGLHLR | Sus scrofa (Pig) |
4 | 394.73 | 14.7 | 2 | LDKWNL | Sus scrofa (Pig) |
5 | 438.24 | 15.3 | 2 | SLDKRAK | - |
6 | 465.71 | 15.4 | 2 | DDFNPSVH | Sus scrofa (Pig) |
7 | 490.23 | 15.9 | 1 | GPLCT | Sus scrofa (Pig) |
No. | m/z | RT (min) | Charge | Sequence | 가수분해물 내 함량 (ppm) |
PEP-1 | 445.27 | 9.4 | 1 | VVVE (서열번호 1) | 10-19 ppm |
PEP-2 | 355.70 | 14.3 | 2 | DGLHLR (서열번호 2) | 4-10 ppm |
PEP-3 | 465.71 | 15.3 | 2 | DDFNPSVH (서열번호 3) | 10-21 ppm |
시료농도 | PEP-1 | PEP-2 | PEP-3 | ||
합성샘플 | sequence | - | VVVE | DGLHLR | DDFNPSVH |
시험농도설정 | 세포독성 (HepG2) | 0.01~1000 ug/ml | ~10ug/ml | ~10ug/ml | ~10ug/ml |
간지표 | 간세포 보호능 |
0.1 ug/ml | ND | 15% | 9% |
1 ug/ml | ND | 20% | 20% | ||
10 ug/ml | 7% | 26% | 20% | ||
AST 억제능 | 0.1 ug/ml | ND | 4% | ND | |
1 ug/ml | ND | 15% | 5% | ||
10 ug/ml | 2% | 34% | 14% | ||
ALT 억제능 | 0.01 ug/ml | ND | 21% | ND | |
0.1 ug/ml | ND | 30% | ND | ||
1 ug/ml | ND | 34% | ND |
구분 | 세포독성 | 간세포보호능 | AST 억제능 | ALT 억제능 |
효소 가수분해물 | 무독성 (0.5mg/ml) |
약 40% 보호 (0.05mg/ml) |
91% (0.1mg/ml) |
23% (0.1mg/ml) |
산 분해물 | 무독성 (0.5mg/ml) |
약 21% 보호 (0.05mg/ml) |
93% (0.1mg/ml) |
변화없음 (0.1mg/ml) |
구분 | 총 질소(mg/mL) | 아미노산(mg/mL) | 아미노산 % | 펩타이드 % |
효소 + 산 (1:1) | 5.47 | 15.73 | 59.4 | 40.6 |
효소 + 산 (1:2) | 5.52 | 17.54 | 65.8 | 34.2 |
효소 + 산 (1:3) | 5.58 | 18.10 | 66.4 | 33.6 |
효소 + 산 (1:4) | 5.61 | 18.62 | 68.2 | 31.8 |
구분 | 총 질소(mg/mL) | 아미노산 (mg/mL) | 아미노산 % | 펩타이드 % |
효소 가수분해물 | 46.79 | 125.25 | 42.5 | 57.5 |
산 분해물 | 35.70 | 197.38 | 81.2 | 18.8 |
효소 및 산 분해물 (1:3)의 혼합물 | 39.27 | 176.27 | 64.0 | 36.0 |
Albumin | ALP | ALT(GPT) | AST(GOT) | Total protein | ||
정상군 | 2.24±0.13 | 483.60±119.02 | 33.66±3.11 | 81.37±3.24 | 5.32±0.31 | |
음성대조군 | 2.38±0.08 | 633.73±91.97 | 115.56±38.96 | 235.03±113.98 | 5.44±0.14 | |
양성대조군 | 2.37±0.13 | 555.63±108.75 | 83.94±28.54 | 126.70±23.81 | 5.24±0.28 | |
돈태반 효소 및 산(1:3) 혼합물 |
고용량 | 2.33±0.22 | 552.89±94.56 | 73.64±10.15 | 139.17±17.64 | 5.19±0.46 |
중용량 | 2.34±0.18 | 490.23±82.20 | 68.76±21.50 | 123.97±25.76 | 5.22±0.34 | |
저용량 | 2.39±0.12 | 568.11±85.03 | 56.91±13.99 | 122.83±17.23 | 5.32±0.27 | |
효소 가수분해물 | 2.42±0.19 | 471.36±99.17 | 82.54±31.70 | 227.31±90.21 | 5.42±0.35 | |
산 분해물 | 2.42±0.10 | 556.39±55.71 | 78.81±11.32 | 169.36±10.36 | 5.31±0.31 |
Claims (7)
- 돈태반 효소 가수분해물과 산 분해물의 혼합물을 유효성분으로 포함하는 간 보호용 건강기능식품 조성물.
- 돈태반 효소 가수분해물과 산 분해물의 혼합물을 유효성분으로 포함하는 알코올로 인한 간 손상, 약물중독 또는 숙취의 예방 또는 개선용 건강기능식품 조성물.
- 제 1 항에 있어서,상기 돈태반 효소 가수분해물은 서열번호 1 내지 서열번호 3으로 이루어진 군에서 선택되는 아미노산 서열로 이루어진 하나 이상의 펩타이드를 포함하는 것인 조성물.
- 제 1 항에 있어서,상기 돈태반 효소 가수분해물은 단백질 가수분해효소를 처리하여 제조된 것인 조성물.
- 제 1 항에 있어서,상기 돈태반 산 분해물은 산(acid)을 처리하여 제조된 것인 조성물.
- 제 5 항에 있어서,상기 산(acid)는 염산, 황산, 아세트산 또는 구연산인 것인 조성물.
- 제 1 항에 있어서,상기 돈태반 효소 가수분해물 및 산 분해물은 1:0.1~10의 중량비로 혼합된 것인 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2021/008308 WO2023277222A1 (ko) | 2021-06-30 | 2021-06-30 | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 |
CN202180099665.0A CN117561003A (zh) | 2021-06-30 | 2021-06-30 | 包含猪胎盘酶水解物和酸水解物的混合物的用于保护肝的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2021/008308 WO2023277222A1 (ko) | 2021-06-30 | 2021-06-30 | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023277222A1 true WO2023277222A1 (ko) | 2023-01-05 |
Family
ID=84692797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/008308 WO2023277222A1 (ko) | 2021-06-30 | 2021-06-30 | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117561003A (ko) |
WO (1) | WO2023277222A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101505861B1 (ko) * | 2012-06-22 | 2015-03-27 | 호서대학교 산학협력단 | 돈태반 가수분해물을 유효성분으로 함유하는 간 보호용 조성물 |
KR102252955B1 (ko) * | 2019-12-13 | 2021-05-17 | 유바이오주식회사 | 돈태반 유래 펩타이드를 포함하는 돈태반 가수분해물 및 간 보호용 조성물 |
KR102283751B1 (ko) * | 2019-12-27 | 2021-07-30 | 유바이오주식회사 | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 |
-
2021
- 2021-06-30 WO PCT/KR2021/008308 patent/WO2023277222A1/ko active Application Filing
- 2021-06-30 CN CN202180099665.0A patent/CN117561003A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101505861B1 (ko) * | 2012-06-22 | 2015-03-27 | 호서대학교 산학협력단 | 돈태반 가수분해물을 유효성분으로 함유하는 간 보호용 조성물 |
KR102252955B1 (ko) * | 2019-12-13 | 2021-05-17 | 유바이오주식회사 | 돈태반 유래 펩타이드를 포함하는 돈태반 가수분해물 및 간 보호용 조성물 |
KR102283751B1 (ko) * | 2019-12-27 | 2021-07-30 | 유바이오주식회사 | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 |
Non-Patent Citations (2)
Title |
---|
HYUN‐JIN KIM; SEMI KIM; JIN‐SOOK SEO; GUN‐WON BAE; KEUN‐NAM KIM; JU‐SEOP KANG: "Effect of Single‐Dose, Oral Enzymatic Porcine Placental Extract on Pharmacokinetics of Alcohol and Liver Function in Rats", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., WILEY-BLACKWELL PUBLISHING, INC., US, vol. 44, no. 5, 11 April 2020 (2020-04-11), US , pages 1018 - 1024, XP071479940, ISSN: 0145-6008, DOI: 10.1111/acer.14319 * |
KANG, Ju-Seop et al. Effect of the porcine placental extract (PPE) on pharmacokinetics of alcohol and mixture [UniA-PlacentaⓇ, Enzymatic Extract : Acid extract=1:3] on alcohol-induced hepatotoxicity in the rat. 아시아 태평양 알코올 및 중독학회 (Asia-Pacific Society for Alcohol and Addiction Research) Biennial Conference. Malaysia. 27-30 November 2019. * |
Also Published As
Publication number | Publication date |
---|---|
CN117561003A (zh) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012134126A2 (en) | Use of compounds isolated from morus bark | |
WO2012074183A1 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
WO2020218720A1 (ko) | 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물 | |
WO2013024950A1 (ko) | 누에탈지번데기 가수분해물을 포함하는 항비만 조성물 및 이를 제조하는 방법 | |
WO2017061840A1 (ko) | 지용성 폴리페놀 성분이 증가된 생약 조성물 제조방법, 상기 방법으로 제조된 생약 조성물, 및 이의 용도 | |
WO2020256464A1 (ko) | 항염 활성을 갖는 아피오스 아메리카나 괴경 추출물의 분획물의 알코올성 위염 예방 또는 치료제로서의 용도 및 이의 제조방법 | |
WO2023277222A1 (ko) | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 | |
KR102283751B1 (ko) | 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물 | |
WO2022139529A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
KR102252955B1 (ko) | 돈태반 유래 펩타이드를 포함하는 돈태반 가수분해물 및 간 보호용 조성물 | |
WO2021080388A1 (ko) | 커큐미노이드계 화합물, 및 감초 추출물 또는 이의 분획물을 포함하는 복합체를 포함하는 돼지 유행성 설사 바이러스 감염의 예방 또는 치료용 조성물 | |
WO2018105998A1 (ko) | 플라보노이드 유도체 화합물을 유효성분으로 함유하는 남성 불임증 예방 및 치료용 조성물 및 이의 용도 | |
WO2021080298A1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2016190689A2 (ko) | 근육 질환 예방, 개선 또는 치료용 또는 근 기능 개선용 조성물 | |
WO2021040416A1 (ko) | 비쑥 추출물을 유효성분으로 포함하는 골대사성 질환으로 유발된 골소실 예방 또는 치료용 약제학적 조성물 | |
WO2021201507A1 (ko) | 갈색거저리 유충 단백질 또는 이의 가수분해물을 유효성분으로 포함하는 근감소증의 예방, 개선 또는 치료용 조성물 | |
WO2022146016A1 (ko) | Nk 세포를 포함한 면역 세포 활성을 우수하게 증진시키는 면역 강화 녹용 효소분해 추출물 | |
WO2023085820A2 (ko) | 근육 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022265281A1 (ko) | 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 | |
WO2018105999A1 (ko) | 이리도이드 유도체 화합물을 유효성분으로 함유하는 남성 불임증 예방 및 치료용 조성물 및 이의 용도 | |
WO2023080553A1 (ko) | 생리 활성을 갖는 펩타이드 및 그의 용도 | |
WO2024049115A1 (ko) | 녹용 효소분해 추출물(henkiv®)을 이용한 운동수행능력 향상 또는 피로 회복용 식품 조성물 | |
WO2019078381A1 (ko) | 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 근육감퇴, 약화 및 근위축 예방, 개선 또는 치료용 약학 조성물, 식품 조성물 및 식품첨가제 | |
WO2018066969A1 (ko) | 아라자임을 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2013022178A1 (ko) | 발효 또는 미발효된 금은화 및 진피 혼합생약 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21948522 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023131970 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180099665.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2024523376 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |